Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 2, 2013, Pages 103-125

  Petrelli, Riccardo ^a   Vita, Patrizia ^a   Torquati, Ilaria ^a   Felczak, Krzysztof ^b   Wilson, Daniel J ^b   Franchetti, Palmarisa ^a   Cappellacci, Loredana ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anticancer; Antiviral; Chemotherapy; Immunosuppression; IMP deydrogenase; IMPDH; Inhibitor design

Indexed keywords

5 ETHYNYL 1 BETA RIBOFURANOSYLIMIDAZOLE 4 CARBOXAMIDE; 7 METHOXY 6 OXAZOL 5 YL 1H QUINAZOLINE 2,4 DIONE DERIVATIVE; ACRIDONE; AVN 944; BENZAMIDE RIBOSIDE; BMS 337197; BMS 566419; CARBAMIC ACID DERIVATIVE; GEMCITABINE; GUANINE NUCLEOTIDE; IMIDAZO[4,5 E][1,4]DIAZAPINE; INDANOCINE; INDOLE DERIVATIVE; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; MERIMEPODIB; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID PHOSPHONATE DERIVATIVE; MYCOPHENOLIC ADENINE DINUCLEOTIDE DERIVATIVE; OXAZOLE DERIVATIVE; PEGINTERFERON ALPHA2A; PHENYLOXAZOLE DERIVATIVE; QUINAZOLINETHIONE DERIVATIVE; QUINOLONE DERIVATIVE; RIBAVIRIN; SELENAZOFURIN; TIAZOFURIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 148;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG DATABASE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PATENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 84875313971     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308020001     Document Type: Review

References (143)

1. Chen L, Petrelli R, Felczak K, Gao G, Bonnac L, Yu JS, et al. Nicotinamide adenine dinucleotide based therapeutics. Curr Med Chem 2008; 15: 650-70.
2. Hedstrom L. IMP dehydrogenase: Structure, mechanism, and inhibition. Chem Rev 2009; 109: 2903-28.
3. Felczak K, Pankiewicz KW. Rehab of NAD(P)-dependent enzymes with NAD(P)-based inhibitors. Curr Med Chem 2011; 18: 1891-908.
4. Pankiewicz KW. NAD and its role in biology and medicine. Curr Med Chem 2011; 18: 1890.
5. Hedstrom L, Gan L. IMP dehydrogenase: Structural schizophrenia and an unusual base. Curr Opin Chem Biol 2006; 10: 520-5.
6. Hedstrom L, Liechti G, Goldberg JB, Gollapalli DR. The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors. Curr Med Chem 2011; 18: 1909-18.
7. Braun-Sand SB, Peetz M. Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics. Future Med Chem 2010; 2: 81-92.
8. Nair V, Shu Q. Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery. Antivir Chem Chemother 2007; 18: 245-58.
9. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975; 256: 331-3.
10. Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenases as drug targets. Ann NY Acad Sci 1993; 696: 88-93.
11. Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM. Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design. Proc Natl Acad Sci USA 1999; 96: 3531-6.
12. Zhang R, Evans G, Rotella FJ, Westbrook EM, Beno D, Huberman E, et al. Characteristics and crystal structure of bacterial inosine-5'-monophosphate dehydrogenase. Biochemistry 1999; 38: 4691-700.
13. McMillan FM, Cahoon M, White A, Hedstrom L, Petsko GA, Ringe D. Crystal structure at 2.4 A resolution of Borrelia burgdorferi inosine 5'-monophosphate dehydrogenase: Evidence of a substrate-induced hinged-lid motion by loop 6. Biochemistry 2000; 39: 4533-42.
14. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921-30.
15. + orients the active site loop for catalysis. Biochemistry 2002; 41: 13309-17.
16. Mortimer SE, Xu D, McGrew D, Hamaguchi N, Lim HC, Bowne SJ, et al. IMP dehydrogenase type 1 associates with polyribosomes translating rhodopsin mRNA. J Biol Chem 2008; 283: 36354-60.
17. McLean JE, Hamaguchi N, Belenky P, Mortimer SE, Stanton M, Hedstrom L. Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo. Biochem J 2004; 379: 243-51.
18. Chen L, Pankiewicz KW. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel 2007; 10: 403-12.
19. Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ Jr, et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006; 49: 2677-80.
20. Maurya SK, Gollapalli DR, Kirubakaran S, Zhang M, Johnson CR, Benjamin NN, et al. Triazole inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem 2009; 52: 4623-30.
21. Chen L, Wilson DJ, Xu Y, Aldrich CC, Felczak K, Sham YY, et al. Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis. J Med Chem 2010; 53: 4768-78.
22. Shu Q, Nair V. Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med Res Rev 2008; 28: 219-32.
23. Grifantini M. Tiazofurin ICN pharmaceuticals. Curr Opin Investig Drugs 2000; 1: 257-62.
24. Franchetti P, Cappellacci L, Grifantini M, Barzi A, Nocentini G, Yang H, et al. Furanfurin and thiophenfurin: Two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase. J Med Chem 1995; 38: 3829-37.
25. Franchetti P, Cappellacci L, Grifantini M. IMP Deydrogenase as a target of antitumor and antiviral chemotherapy. Farmaco 1996; 51: 457-69.
26. Franchetti P, Cappellacci L, Abu Sheikha G, Jayaram HN, Gurudutt VV, Sint T, et al. Synthesis, structure, and antiproliferative activity of selenophenfurin, an inosine 5'-monophosphate dehydrogenase inhibitor analogue of selenazofurin. J Med Chem 1997; 40: 1731-7.
27. Franchetti P, Marchetti S, Cappellacci L, Jayaram HN, Yalowitz JA, Goldstein BM, et al. Synthesis, conformational analysis, and biological activity of C-thioribonucleosides related to tiazofurin. J Med Chem 2000; 43: 1264-70.
28. Franchetti P, Marchetti S, Cappellacci L, Yalowitz JA, Jayaram HN, Goldstein BM, et al. A new C-nucleoside analogue of tiazofurin: Synthesis and biological evaluation of 2-beta-Dribofuranosylimidazole-4-carboxamide (imidazofurin). Bioorg Med Chem Lett 2001; 11: 67-9.
29. Franchetti P, Pasqualini M, Cappellacci L, Petrelli R, Vita P, Jayaram HN, et al. Ribose-modified mizoribine analogues: Synthesis and biological evaluation. Nucleosides Nucleotides Nucleic Acids 2005; 24: 2023-7.
30. Franchetti P, Cristalli G, Grifantini M, Cappellacci L, Vittori S, Nocentini G. Synthesis and antitumor activity of 2-beta-Dribofuranosyloxazole-4-carboxamide (oxazofurin). J Med Chem 1990; 33: 2849-52.
31. Goldstein BM, Li H, Hallows WH, Langs DA, Franchetti P, Cappellacci L, et al. C-glycosyl bond conformation in oxazofurin: Crystallographic and computational studies of the oxazole analogue of tiazofurin. J Med Chem 1994; 37: 1684-8.
32. Franchetti P, Cappellacci L, Perlini P, Jayaram HN, Butler A, Schneider BP, et al. Isosteric analogues of nicotinamide adenine dinucleotide derived from furanfurin, thiophenfurin, and selenophenfurin as mammalian inosine monophosphate dehydrogenase (type I and II) inhibitors. J Med Chem 1998; 41: 1702-7.
33. Franchetti P, Cappellacci L, Marchetti S, Trincavelli L, Martini C, Mazzoni MR, et al. 2'-C-Methyl analogues of selective adenosine receptor agonists: Synthesis and binding studies. J Med Chem 1998; 41: 1708-15.
34. Cappellacci L, Franchetti P, Pasqualini M, Petrelli R, Vita P, Lavecchia A, et al. Synthesis, biological evaluation and molecular modeling of ribose-modified adenosine analogues as adenosine receptors agonists. J Med Chem 2005; 48: 1550-62.
35. Franchetti P, Cappellacci L, Pasqualini M, Petrelli R, Vita P, Jayaram HN. Antitumor activity of C-methyl-β-D-ribofurano syladenine nucleoside ribonucleotide reductase inhibitors. J Med Chem 2005; 48: 4983-9.
36. Franchetti P, Cappellacci L, Pasqualini M, Petrelli R, Jayaprakasan V, Jayaram HN, et al. Synthesis, conformational analysis, and biological activity of new analogues of thiazole-4-carboxamide adenine dinucleotide (TAD) as IMP dehydrogenase inhibitors. Bioorg Med Chem 2005; 13: 2045-53.
37. Chen L, Gao G, Bonnac L, Wilson DJ, Bennett EM, Jayaram HN, et al. Methylenebis(sulfonamide) linked nicotinamide adenine dinucleotide analogue as an inosine monophosphate dehydrogenase inhibitor. Bioorg Med Chem Lett 2007; 17: 3152-5.
38. Lesiak K, Watanabe KA, Majumdar A, Powell J, Seidman M, Vanderveen K, et al. Synthesis of a methylenebis(phosphonate) analogue of mycophenolic adenine dinucleotide: A glucuronidation-resistant MAD analogue of NAD. J Med Chem 1998; 41: 618-22.
39. Marquez VE, Tseng CK, Gebeyehu G, Cooney DA, Ahluwalia GS, Kelley JA, et al. Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogues stable to phosphodiesterase hydrolysis. J Med Chem 1986; 29: 1726-31.
40. Chen L, Petrelli R, Olesiak M, Wilson DJ, Labello NP, Pankiewicz KW. Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: Inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem 2008; 16: 7462-9.
41. + biosynthesis. Biochemistry 2007; 46: 4912-22.
42. Petrelli R, Sham YY, Chen L, Felczak K, Bennett E, Wilson D, et al. Selective inhibition of nicotinamide adenine dinucleotide kinases by dinucleoside disulfide mimics of nicotinamide adenine dinucleotide analogues. Bioorg Med Chem 2009; 17: 5656-64.
43. Petrelli R, Felczak K, Cappellacci L. NMN/NaMN adenylyltransferase (NMNAT) and NAD kinase (NADK) inhibitors: chemistry and potential therapeutic applications. Curr Med Chem 2011; 18: 1973-92.
44. Khanna N, Jayaram HN, Singh N. Benzamide riboside induced mitochondrial mediated apoptosis in human lung cancer H520 cells. Life Sci 2004; 75: 179-90.
45. Chen L, Gao G, Felczak K, Bonnac L, Patterson SE, Wilson D, et al. Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues. J Med Chem 2007; 50: 5743-51.
46. Rejman D, Olesiak M, Chen L, Patterson SE, Wilson D, Jayaram HN, et al. Novel methylenephosphophosphonate analogues of mycophenolic adenine dinucleotide. Inhibition of inosine monophosphate dehydrogenase. J Med Chem 2006; 49: 5018-22.
47. Sintchak MD, Nimmesgern E. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47: 163-84.
48. Jain J, Almquist SJ, Heiser AD, Shlyakhter D, Leon E, Memmott C, et al. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther 2002; 302: 1272-7.
49. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, et al. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 2005; 24: 5888-96.
50. Floryk D, Thompson TC. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer 2008; 123: 2294-302.
51. Floryk D, Tollaksen SL, Giometti CS, Huberman E. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5'-monophosphate dehydrogenase. Cancer Res 2004; 64: 9049-56.
52. Chen P, Norris D, Haslow KD, Murali Dhar TG, Pitts WJ, Watterson SH, et al. Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors. Bioorg Med Chem Lett 2003; 13: 1345-8.
53. Gu HH, Iwanowicz EJ, Guo J, Watterson SH, Shen Z, Pitts WJ, et al. Novel diamide-based inhibitors of IMPDH. Bioorg Med Chem Lett 2002; 12: 1323-6.
54. Dhar TG, Shen Z, Gu HH, Chen P, Norris D, Watterson SH, et al. 3-Cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: Synthesis and initial structure-activity relationships. Bioorg Med Chem Lett 2003; 13: 3557-60.
55. Iwanowicz EJ, Watterson SH, Liu C, Gu HH, Mitt T, Leftheris K, et al. Novel guanidine-based inhibitors of inosine monophosphate dehydrogenase. Bioorg Med Chem Lett 2002; 12: 2931-4.
56. Watterson SH, Dhar TG, Ballentine SK, Shen Z, Barrish JC, Cheney D, et al. Novel indole-based inhibitors of IMPDH: Introduction of hydrogen bond acceptors at indole C-3. Bioorg Med Chem Lett 2003; 13: 1273-6.
57. Pickett SD, Sherborne BS, Wilkinson T, Bennett J, Borkakoti N, Broadhurst M, et al. Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg Med Chem Lett 2003; 13: 1691-4.
58. Watkins WJ, Chen JM, Cho A, Chong L, Collins N, Fardis M, et al. Phosphonic acid-containing analogues of mycophenolic acid as inhibitors of IMPDH. Bioorg Med Chem Lett 2006; 16: 3479-83.
59. Beevers RE, Buckley GM, Davies N, Fraser JL, Galvin FC, Hannah DR, et al. Novel indole inhibitors of IMPDH from fragments: Synthesis and initial structure-activity relationships. Bioorg Med Chem Lett 2006; 16: 2539-42.
60. Birch HL, Buckley GM, Davies N, Dyke HJ, Frost EJ, Gilbert PJ, et al. Novel 7-methoxy-6-oxazol-5-yl-2,3-dihydro-1H-quinazolin-4-ones as IMPDH inhibitors. Bioorg Med Chem Lett 2005; 15: 5335-9.
61. Buckley GM, Davies N, Dyke HJ, Gilbert PJ, Hannah DR, Haughan AF, et al. Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: Synthesis and initial structure-activity relationships. Bioorg Med Chem Lett 2005; 15: 751-4.
62. Armer RE, Cowley PM. Trends in medicinal chemistry 2004. Drug News Perspect 2005; 18: 142-8.
63. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006; 57: 8-13.
64. Hong Z, Cameron CE. Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 2002; 59: 41-69.
65. Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem 1999; 6: 575-97.
66. Gan L, Seyedsayamdost MR, Shuto S, Matsuda A, Petsko GA, Hedstrom L. The immunosuppressive agent mizoribine monophosphate forms a transition state analogue complex with inosine monophosphate dehydrogenase. Biochemistry 2003; 42: 857-63.
67. Wang W, Papov VV, Minakawa N, Matsuda A, Biemann K, Hedstrom L. Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate. Biochemistry 1996; 35: 95-101.
68. Balzarini J, Stet L, Matsuda A, Wiebe L, Knauss E, De Clercq E. Metabolism of EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide), a potent inhibitor of inosinate dehydrogenase. Adv Exp Med Biol 1998; 431: 723-8.
69. Wang W, Hedstrom L. A potent "fat base" nucleotide inhibitor of IMP dehydrogenase. Biochemistry 1998; 37: 11949-52.
70. Armistead, D.M., Badia, M., Bemis, G.W., Bethiel, R.S., Frank, C.A., Novak, P.M., Ronkin, S.M., Saunders, J.O. Preparation of arylureas and related compounds as inhibitors of inosine 5'-monophosphate dehydrogenase. WO9740028 (1997).
71. Jain-Pandey, J., Fram, R.J. Composition comprising inhibitors of IMPDH enzyme. WO2004052349 (2004).
72. Saunders, J., Elbaum, D., Novak, P., Naegele, D., Bethiel, R.S., Ronkin, S.M., Badia, M., Frank, C., Stamos, D., Walters, W., Pearlman, D. Benzamide, naphthalenecarboxamide, arylacetamide, arenesulfonamide, carbamate, thiocarbamate, and benzylamine inhibitors of inosine-5'-monophosphate dehydrogenase. WO9955663 (1999).
73. Armistead, D.M., Badia, M., Bemis, G.W., Bethiel, R.S., Frank, C.A., Novak, P.M., Ronkin, S.M., Saunders, J.O. Inhibitors of IMPDH enzyme. US20030195202 (2003) & US20050282876 (2005).
74. Saunders, J.O., Armistead, D.M., Badia, M., Bethiel, R.S., Frank, C.A., Naegele, D., Novak, P.M., Pearlman, D., Ronkin, S.M. Inhibitors of IMPDH enzyme. US20040048774 (2004).
75. Saunders, J.O., Armistead, D.M., Badia, M.C., Bethiel, R.S., Frank, C.A., Naegele, D., Novak, P.M., Pearlman, D.A., Ronkin, S.M. Preparation of heterocyclic compounds as inhibitors of inosine-5'-monophosphate dehydrogenase (IMPDH). WO9840381 (1998).
76. Stamos, D.P., Bethiel, R.S. Inhibitors of IMPDH enzyme. US20090093639 (2009).
77. Pitts WJ, Guo J, Dhar TG, Shen Z, Gu HH, Watterson SH, et al. Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase. Bioorg Med Chem Lett 2002; 12: 2137-40.
78. Watterson SH, Liu C, Dhar TG, Gu HH, Pitts WJ, Barrish JC, et al. Novel amide-based inhibitors of inosine 5'-monophosphate dehydrogenase. Bioorg Med Chem Lett 2002; 12: 2879-82.
79. Dhar TG, Shen Z, Guo J, Liu C, Watterson SH, Gu HH, et al. Discovery of N-[2-[2-[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. J Med Chem 2002; 45: 2127-30.
80. Liu, C., Dhar, T.G., Gu, H.H., Iwanowicz, E.J., Leftheris, K., Pitts, W.J. Preparation of compounds derived from an amine nucleus as inhibitors of IMPDH enzyme. WO00025780 (2000).
81. Watterson, S.H., Dhar, T.G., Iwanowicz, E.J. 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same. WO03099206 (2003).
82. Liu, C. Process for prepartion of tri-nitrogen containing heteroaryldiamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents. WO2004032875 (2004).
83. Gu, H.H., Dhar, T.G., Iwanowicz, E.J. Novel inhibitors of IMPDH enzyme. US20040102497 (2004).
84. Gu, H.H., Dhar, T.G., Iwanowicz, E.J. Preparation of N-[4-(5-oxazolyl)phenyl] amides as novel inhibitors of IMPDH enzyme. WO00026197 (2000).
85. Iwanowicz, E.J., Watterson, S.H., Dhar, T.G., Pitts, W.J., Gu, H.H. Preparation of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme. WO01081340 (2001).
86. Dhar TG, Watterson SH, Chen P, Shen Z, Gu HH, Norris D, et al. Quinolone-based IMPDH inhibitors: Introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues. Bioorg Med Chem Lett 2003; 13: 547-51.
87. Watterson SH, Carlsen M, Dhar TG, Shen Z, Pitts WJ, Guo J, et al. Novel inhibitors of IMPDH: A highly potent and selective quinolone-based series. Bioorg Med Chem Lett 2003; 13: 543-6.
88. Haughan, A.F., Dyke, H.J., Buckley, G.M., Davies, N., Hannah, D.R., Richard, M.D., Sharpe, A., Williams, S.C. Quinolone derivatives. US20030105073 (2003).
89. Dyke, H.J., Richard, M.D., Haughan, A.F., Sharpe, A. Preparation of quinazolinedione derivatives as inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors for use in pharmaceutical compositions. WO03053958 (2003).
90. Haughan, A.F., Buckley, G.M., Dyke, H.J., Hannah, D.R., Richard, M.D., Sharpe, A., Williams, S.C. Quinazolinone derivatives. WO2004018462 (2004).
91. Haughan, A.F., Buckley, G.M., Davies, N., Dyke, H.J., Hannah, D.R., Morgan T., Richard, M.D., Sharpe, A., Williams, S.C. Quinazolinone derivatives. WO2004022554 (2004).
92. Buckley, G.M., Dyke, H.J. Guanidine derivatives. WO03045901 (2003).
93. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005; 49: 1898-906.
94. Cannizzaro, C.E., Chen, J.M., Chen, X., Cho, A., Chong, L.S., Fardis, M., Kirschberg, T.A., Pyun, H., Watkins, W., Zhang, J.R. Preparation of phosphonic acid derivatives of inosine monophosphate dehydrogenase inhibitors as prodrugs. WO2004096287 (2004).
95. Cho, A., Kirschberg, T.A., Watkins, W., Fardis, M., Chong, L.S. Preparation of mycophenolic acid phosphonate derivatives as anticancer, anti-viral, anti-inflammatory and immunosuppressive agents. WO2005039552 (2005).
96. Iwanowicz, E.J., Watterson, S.H., Chen, P., Dhar, T.G., Gu, H.H., Zhao, Y. Acridone inhibitors of IMPDH enzyme. WO03059269 (2003) & US20040053955 (2004).
97. Chen, P., Dhar, T.G., Iwanowicz, E.J., Watterson, S.H., Gu, H.H., Zhao, Y. Heterocyclic acridone inhibitors of IMPDH enzyme. US20030181497 (2003).
98. Watterson SH, Chen P, Zhao Y, Gu HH, Dhar TG, Xiao Z, et al. Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419). J Med Chem 2007; 50: 3730-42.
99. Haughan, A.F., Dyke, H.J., Williams, S.C., Lowe, C., Draffan, A.G., Owen, D.A. Sulfonamide derivatives. WO03087071 (2003).
100. Behrend M, Braun F. Enteric-coated mycophenolate sodium: Tolerability profile compared with mycophenolate mofetil. Drugs 2005; 65: 1037-50.
101. Chan L, Mulgaonkar S, Walker R, Arns W, Ambuhl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and healthrelated quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81: 1290-7.
102. Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil versus entericcoated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: One year follow-up. Transplantation 2008; 86: 67-74.
103. Stamos, D.P., Bethiel, R.S. Prodrugs of carbamate inhibitors of IMPDH. WO0100622 (2001), US20050101664 (2005) & US20090093639 (2009).
104. Carson, D.A., Leoni, L.M., Cottam, H.B. New uses for inhibitors of inosine monophosphate dehydrogenase. WO2004012746 (2004).
105. Carson, D.A., Leoni, L.M., Cottam, H.B. Uses for inhibitors of inosine monophosphate dehydrogenase. US20040127435 (2004).
106. Jain-Pandey, J., Fram, R.J. Compositions comprising inhibitors of inosine-5'-monophosphate dehydrogenase (IMPDH) and an antitumor agent, and use in the treatment of cancer. US20050059734 (2005).
107. Purifoy, T., Strovel, J., Chakiat, M., Bol, D., Castaneda, J., Natarajan, P. Cancer-linked genes as biomarkers to monitor response to IMPDH inhibitors. WO2008070160 (2008).
108. Jain-Pandey, J., Harding, M.W., Ramachandran, R., Botfield, M., Kelliher, K., Shames, B. Biomarkers for monitoring inhibiton of IMPDH pathway. WO2005117943 (2005).
109. Roepman, P., Glas, A.M. Methods and means for typing a sample comprising colorectal cancer cells. US201110319285 (2011)
110. Carson, D.A., Cottam, H.B., Lee, J. Combined use of IMPDH inhibitors with toll-like receptor agonists. US20050004144 (2005).
111. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27: 190-9.
112. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, et al. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007; 47: 174-82.
113. Meunier B. Hybrid molecules with a dual mode of action: Dream or reality? Acc Chem Res 2008; 41: 69-77.
114. Meli M, Tolomeo M, Grifantini M, Mai A, Cappellacci L, Petrelli R, et al. Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3α-C-methyladenosine in leukaemia cells. Int J of Oncol 2011; 38: 1427-36.
115. Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M. Histone deacetylase inhibitors: A new wave of molecular targeted anticancer agents. Recent Pat Anticancer Drug Discov 2007; 2: 119-34.
116. Pankiewicz, K.W., Chen, L., Vince, R. Anticancer agents. WO2009018344 (2009).
117. Chen L, Petrelli R, Gao G, Wilson DJ, McLean GT, Jayaram HN, et al. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg Med Chem 2010; 18: 5950-64.
118. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 2011; 226: 2378-90.
119. Almstead, N., Choi, S., Campbell, J., Corson, D., Graci, J.D., Hwang, P., Lennox, W., Miao, H.H., Miller, L., Moon, Y.-C., Trotta, C., Weetall, M.L. Methods for treating cancer and nonneoplastic conditions. WO2010138758 (2010).
120. Cao, L., Hirawat, S., Miao, H.H., Miller, L., Romfo, C., Weetall, M.L. Methods for treating breast cancer. WO2010138706 (2010).
121. Cao, L., Davis, T.W., Miao, H.H., Miller, L., Weetall, M.L. Methods for treating neurofibromatosis. WO2010138695 (2010).
122. Cao, L., Davis, T.W., Hirawat, S., Miao, H.H., Miller, L., Romfo, C., Weetall, M.L. Methods for treating prostate conditions. WO2010138685 (2010).
123. Cao, L., Davis, T.W., Hirawat, S., Miao, H.H., Miller, L., Weetall, M.L. Methods for treating brain tumors. WO2010138659 (2010).
124. Cao, L., Davis, T.W., Hirawat, S., Miao, H.H., Miller, L., Weetall, M.L. Methods for treating kaposi sarcoma. WO2010138652 (2010).
125. Rodríguez-Pascual, Sha P, García-García E, Rajeshkumar NV, De Vicente E, Quijano Y, et al. A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Invest New Drugs 2012; doi 10.1007/s10637-012-9822-x.
126. Bergstein, I. Novel methods of cancer diagnosis and therapy targeted against a cancer stem line. US201110318351 (2011).
127. Bergstein, I. Methods of cancer therapy targeted against a cancer stem line. US8038998 (2011).
128. Sayada, C. Administration of rifalazil to immunocompromised patients. WO2012011917 (2012).
129. Porter, S.B., Bradford, W.Z., Smith, P.F., Yetzer, E.S., De La Rosa, A., Rogers, M.D., Symonds, W.T. Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis c, liver fibrosis and impaired liver function (as amended). US20120128628 (2012).
130. Hedstrom L. IMP dehydrogenase: Mechanism of action and inhibition. Curr Med Chem 1999; 6: 545-60.
131. Chalkiadaki A. Cell cycle: The double life of IMPDH. Nat Chem Biol 2012; 18; 678.
132. Makowska-Grzyska M, Kim Y, Wu R, Wilton R, Gollapalli DR, Wang XK, et al. Bacillus anthracis IMP dehydrogenase in action: The first bacterial series of structures of phosphate ion-, substrateand product-bound complexes. Biochemistry 2012; 51: 6148-63.
133. Kozhevnikova EN, van der Knaap JA, Pindyurin AV, Ozgur Z, van Ijcken WFJ, Moshkin Yuri M, et al. Metabolic enzyme IMPDH Is also a transcription factor regulated by cellular state. Mol Cell 2012; 47: 133-9.
134. Digits JA, Hedstrom L. Kinetic mechanism of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase. Biochemistry 1999; 38: 2295-306.
135. Carey CM, Lee H, Trevors JT. Biology, persistence and detection of Cryptosporidium parvum and Cryptosporidium hominis oocyst. Water Res 2004; 38: 818-62.
136. Hedstrom, L.K., Striepen, B. Compounds and methods for treating mammalian gastrointestinal parasitic infections. WO2007143557 (2007).
137. Umejiego NN, Gollapalli D, Sharling L, Volftsun A, Lu J, Benjamin NN, et al. Targeting a prokaryotic protein in a eukaryotic pathogen: Identification of lead compounds against cryptosporidiosis. Chem Biol 2008; 15: 70-7.
138. Gollapalli DR, Macpherson IS, Liechti G, Gorla SK, Goldberg JB, Hedstrom L. Structural determinants of inhibitor selectivity in prokaryotic IMP dehydrogenases. Chem Biol 2010; 17: 1084-91.
139. Hedstrom, L.K., Cuny, G.D., Gollapalli, D.R., Kirubakaran, S., Striepen, B., Gorla, S.K., Maurya, S.K., Johnson, C.R., Kavitha, M., Khan, J. Compounds and methods for treating mammalian gastrointestinal microbial infection. WO2010108187 (2010).
140. Sharling L, Liu X, Gollapalli DR, Maurya SK, Hedstrom L, Striepen B. A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase. PLoS Negl Trop Dis 2010; 4: 794-806.
141. Kirubakaran S, Gorla SK, Sharling L, Zhang M, Liu X, Ray SS, et al. Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg Med Chem Lett 2012; 22: 1985-8.
142. Charifson, P., Grossman, T., Perola, E. Inhibitors of bacterial IMPDH. WO2007030617 (2007).
143. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, et al. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res 2004; 10: 8301-8.